GVS advice glucagon (Ogluo®) for the treatment of severe hypoglycaemia in adults and children aged 2 years and older
The National Health Care Institute assessed whether the administration of subcutaneous glucagon (administration under the skin) with a pre-filled pen (Ogluo®) can be included in the Medicine Reimbursement System (GVS). This medicinal product can be used to treat severe hypoglycaemia in adults and children aged 2 years and older. The National Health Care Institute advises the Minister of Health, Welfare and Sport (VWS) to include glucagon on List 1B of the GVS.
Indication for which reimbursement is requested
A prefilled pen with glucagon can be used for severe hypoglycaemia in adults and children aged 2 years and older. Severe hypoglycaemia is a sharp fall in blood glucose levels, requiring help from caregivers, family or relatives to administer the glucagon.
Recommendations from the National Health Care Institute
The National Health Care Institute advises the Minister of VWS to include subcutaneous glucagon in List 1B of the reimbursement conditions of the basic health care package.
Medicine Reimbursement System (GVS)
Glucagon is an extramural drug. Extramural drugs are medicinal products for home use, available at the pharmacy on prescription from a physician. They will only be reimbursed from the basic health care package if they are listed in the GVS. The amount of the reimbursement depends on the list the product is on. Interchangeable medicinal products are clustered in List 1A. These may be subject to a reimbursement limit. Unique medicinal products are listed in List 1B. There is no reimbursement limit for these products. Additional conditions may apply for reimbursement. In that case, a medicinal product is also listed in List 2.
The Scientific Advisory Board (WAR) advises the National Health Care Institute about the assessment. Based on the assessment, the National Health Care Institute sends an advisory report to the Minister of Health, Welfare and Sport. The Minister makes the final decision whether or not to reimburse the medication from the basic health care package.